Register Financial Advisors LLC Makes New Investment in Stryker Co. (NYSE:SYK)

Register Financial Advisors LLC bought a new position in shares of Stryker Co. (NYSE:SYK) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 294 shares of the medical technology company’s stock, valued at approximately $105,000.

Other hedge funds have also modified their holdings of the company. Burkett Financial Services LLC purchased a new position in Stryker in the 4th quarter valued at about $25,000. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. Rogco LP purchased a new position in Stryker in the 4th quarter valued at about $30,000. DSM Capital Partners LLC purchased a new position in Stryker in the 4th quarter valued at about $34,000. Finally, HBC Financial Services PLLC purchased a new position in Stryker in the 4th quarter valued at about $37,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 0.0 %

NYSE SYK traded down $0.11 during mid-day trading on Friday, reaching $340.43. 1,894,420 shares of the stock were exchanged, compared to its average volume of 1,315,695. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The business’s fifty day simple moving average is $337.38 and its 200 day simple moving average is $333.39. The stock has a market capitalization of $129.69 billion, a PE ratio of 38.86, a PEG ratio of 2.68 and a beta of 0.92. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. During the same quarter last year, the business earned $2.14 earnings per share. Stryker’s revenue was up 9.7% compared to the same quarter last year. On average, research analysts anticipate that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.94%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Barclays raised their target price on shares of Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Citigroup raised their price target on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Wells Fargo & Company raised their price target on shares of Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Piper Sandler raised their price target on shares of Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Finally, Robert W. Baird raised their price target on shares of Stryker from $367.00 to $378.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.58.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.